Systems biology and heart failure: concepts, methods, and potential research applications

Adams, Kirkwood F.

doi:10.1007/s10741-009-9138-x

Cited by 20 publications

(19 citation statements)

References 172 publications

(189 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, even more ambitious goal of such approach is to explore how these networks interact with one another as well as with the environment to ultimately determine clinical phenotypes. 63,[438][439][440][441][442] The key concept of systems biology is that these interconnected networks, rather than distinct metabolic pathways, underlie the nature of biological processes.…”

Section: Integrating "Omics": Systems Biology and Network Medicinementioning

confidence: 99%

“…453 Network-based systems biology approaches have started to be applied to gain deep insights into cardiovascular health and disease. 63,438,440,456,457 Such approaches extensively employ genomic, transcriptomic, proteomic and metabolomic analyses. Resultant massive complex data are processed, analyzed and integrated using advanced bioinformatics and computational modeling to build mathematical models of physiological or pathophysiological processes.…”

Section: Integrating "Omics": Systems Biology and Network Medicinementioning

confidence: 99%

“…[458][459][460] Typical work-flow of a systems biology approach applied to CVD is schematically shown in Figure 24.10. 440 Recent network-based analysis of cardiovascular development has revealed complex functional interactions between transcription factors Gata4, Mef2a, Nkx2-5, and Srf. Moreover, histone modifications and miRNAs are also implicated in this regulatory network essential for cardiogenesis.…”

Section: Integrating "Omics": Systems Biology and Network Medicinementioning

confidence: 99%

“…462 Network-based strategy can also be used to assess the pathogenesis of HF and the biomechanical models of this condition have been emerging. 440 In a model system, network-based proteomic analysis has suggested a role for ATP-sensitive K + channel Kir6.2 in cardiac disease susceptibility. 465 Studies of protein interactome associated with dilated cardiomyopathy have also been initiated.…”

Section: Integrating "Omics": Systems Biology and Network Medicinementioning

confidence: 99%

See 3 more Smart Citations

The Path to Personalized Cardiovascular Medicine

Marı́n-Garcı́a

2014

Post-Genomic Cardiology

View full text Add to dashboard Cite

Section: Integrating "Omics": Systems Biology and Network Medicinementioning

confidence: 99%

Section: Integrating "Omics": Systems Biology and Network Medicinementioning

confidence: 99%

Section: Integrating "Omics": Systems Biology and Network Medicinementioning

confidence: 99%

Section: Integrating "Omics": Systems Biology and Network Medicinementioning

confidence: 99%

See 2 more Smart Citations

The Path to Personalized Cardiovascular Medicine

Marı́n-Garcı́a

2014

Post-Genomic Cardiology

View full text Add to dashboard Cite

“…Systems biology is attempting to enable understanding the complex conditions such as HF since it can integrate observations stemming from genes and their respective products and thus could allow the study of cell's organization and its physiological behavior. 1 Concomitantly, a dramatic change in cardiovascular medicine has witnessed a sizable reduction in patients' morbidity and mortality. However, cardiovascular diseases (CVDs) still remain a serious concern globally and disappointingly its manifestation has considerably changed.…”

mentioning

confidence: 99%

Harnessing Investigative Genomics in Heart Failure

Singh¹

2015

JIG

View full text Add to dashboard Cite

which promised to resolve several thousand proteins in a failing heart. However, 2DGE was successful for the abundant and moderately expressed proteins; it struggled to identify proteins expressed at low levels. Nonetheless, first dimension separations combined with advances in mass spectrometry can provide an alternative for solving this issue. 8 In this era of genomics, new technologies and the information they generate have a wide range of potential applications in HF. Though there has not been wide spread use of genomics in everyday practice but there are many examples of how this is beginning to transform the way we look at diseases in terms of diagnosis, prognosis and treatment. The experience from oncology and other fields is helping cardiovascular medicine not only for investigating HF but the reciprocal nature of this can be clinically useful (for instance, predicting treatment responses) to drive laboratory investigations (teasing out the pathways in non-responders to treatments can be a focus of new drug discoveries). 9 As etiology of HF is far more complex than previously realized molecular assays such as gene based micro-arrays coupled with robust algorithm derived from newer bioinformatics tools will provide ample opportunities developing diagnostics and prognostics and also important therapeutics.10 State of the art technologies are currently available to study genetics of CVDs, including mutation screening; genome wide association studies (GWAS) and the recently developed NGS. Genetic mutations of ion channel genes can lead to inheritance of SCD. Thus, further refinement in technology may aid in the development of molecular assays for detecting mutations and single nucleotide polymorphisms (SNPs) which have been shown to be linked with left ventricular hypertrophy (LVH). Also, hypertension (HTN) and obesity are well-established independent contributors for LVH pathology, but they only explain half of the variance of left ventricular mass (LVM) in humans. Clinical evidence suggests that there is a genetic basis to the observed inter-individual variability in the susceptibility for the development of LVH. Given the substantial relationship between LVM and cardiovascular events, elucidating the genetic determinants of inter-individual differences in the susceptibility to LVH is of considerable public health importance because it promises to identify high-risk individuals for targeted intervention and may identify novel targets for improved prevention and treatment.Another cause of HF is the congenital heart defect (CHD), which is also a common cause of morbidity and mortality across countries representing a unique situation in both categorization and protocol management of HF. It remains unclear if the current guidelines for diagnosis and treatment of HF in adults can serve as a meaningful framework for these patients. Additionally, widely used conventional HF therapy of β-blockers and angiotensin converting enzyme (ACE) inhibitors has not demonstrated clear survival benefit and adequately powered a...

show abstract

Treatment preferences in fibromyalgia patients: A cross‐sectional web‐based survey

Valentini

Fetter

Orbell

2020

European Journal of Pain

View full text Add to dashboard Cite

Background: Therapeutic approaches to fibromyalgia (FM) are shifting towards a combined multi-treatment approach to tackle the variety of symptoms experienced in FM. Importantly, little is known about FM patients' attitude towards the available treatments. Methods: A cross-sectional web survey obtained responses from 464 individuals who satisfied diagnostic criteria for FM. Respondents were asked to report which treatments they adopted in their past, present and intend to adopt in the future. They also rated their level of well-being, depression, anxiety and pain catastrophizing. Results: Data revealed a predominantly combined multi-treatment approach in a sample characterized by middle-aged, Caucasian women. Respondents reported pervasive use of pharmacological therapy but had also adopted non-pharmacological treatment in the past. Future intentions clustered on alternative treatment or no treatment. Regression analyses revealed that pharmacological treatment in the past was predictive of both pharmacological and non-pharmacological treatments in the present. However, use of non-pharmacological treatment in the past was uniquely predictive of its reuse in the present and future. This pattern was also accounted for by individual differences in pain magnification and well-being in the past. Conclusions: Treatment preferences of FM individuals reveal an ambivalent combination of heavy reliance on pharmacological treatment with lower but consistent reliance on non-pharmacological treatment for those individuals who used it in the past and present. This finding may inform longitudinal research into the relationship between pharmacological and non-pharmacological treatment preference in FM patients, which could in turn inform guidelines for individualized therapeutic plans for clinicians. Significance: Individuals with fibromyalgia reported the use of non-pharmacological and pharmacological treatments in the past but a predominant use of a pharmacological approach overall. Patterns of treatment experienced in the past were differentially related to future preferences. Pharmacological treatment in the past was likely to lead to both pharmacological and non-pharmacological choices in the present. However, non-pharmacological treatment in the past was more likely to be chosen again in the present and future, but unlikely to lead to a pharmacological choice.

show abstract

Systems biology and heart failure: concepts, methods, and potential research applications

Cited by 20 publications

References 172 publications

The Path to Personalized Cardiovascular Medicine

The Path to Personalized Cardiovascular Medicine

Harnessing Investigative Genomics in Heart Failure

Treatment preferences in fibromyalgia patients: A cross‐sectional web‐based survey

Contact Info

Product

Resources

About